[go: up one dir, main page]

CA2370387A1 - Genetic sequence which codes for the flavon synthase ii enzyme and use of the same - Google Patents

Genetic sequence which codes for the flavon synthase ii enzyme and use of the same Download PDF

Info

Publication number
CA2370387A1
CA2370387A1 CA002370387A CA2370387A CA2370387A1 CA 2370387 A1 CA2370387 A1 CA 2370387A1 CA 002370387 A CA002370387 A CA 002370387A CA 2370387 A CA2370387 A CA 2370387A CA 2370387 A1 CA2370387 A1 CA 2370387A1
Authority
CA
Canada
Prior art keywords
nucleic acid
acid sequence
hybrids
fns
plant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370387A
Other languages
French (fr)
Inventor
Stefan Martens
Gert Forkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370387A1 publication Critical patent/CA2370387A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/825—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving pigment biosynthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

The invention relates to genetic sequences which code for the enzyme of the flavonoid metabolism, in particular, for flavon synthase II (FNS II) or derivates thereof and to their use for specifically modifying the colour of flowers, for modifying the flavon content or expression in leaves, flowers a nd other plant or organic tissue. The use also covers expression systems for synthesising natural, functional flavons for medical or similar applications , for example, for treating cancer or for improving the human immune defence.< /SDOAB>

Description

r GENETIC SEQUENCE WHICH CODES FOR THE FLAVONE SYNTHASE II
ENZYME AND USE OF THE SAME
The present invention relates to genetic sequences encoding enzymes of the flavonoid metabolism, in particular flavone synthase II (FNS II) or derivatives thereof as well as to the use thereof for the targeted modification of the color of flowers, for altering the flavone content or the flavone pattern, respectively, in leaves, flowers and other tissues of plants and other organisms, moreover, it relates to the use in expression systems for the synthesis of natural, functional flavones for medical or similar applications, for example for the treatment of cancer or for improving the human immune defense.
Flavonoids and their function in plants Flavonoids are the most important and most widespread plant pigments which have been detected in various tissues, such as flowers, leaves or roots.
Furthermore, they are among the best characterized secondary metabolites in plants. Up to now, more than 3000 different flavonoids have been characterized.
They have been divided into different subclasses (e.g. flavones, flavonols, or anthocyans) based on the degree of oxidation of the central C ring.
Additionally, each type may be further modified by hydroxylation, acylation or glycosylation (Heller and Forkmann, 1994). Due to the different physico-chemical properties of the molecules, the subclasses may in part exhibit very different biological functions.
The accumulation of certain flavonoids in a plant cell depends on the availability of the corresponding enzymes wherein the availability of the enzymes ultimately is dependent on the expression of the respective gene. Regulation of the expression of the genes of flavonoid biosynthesis is substantially determined by the plant species, the developmental stage and environmental conditions.
Flavonoids play an important role both within and outside of the plant. Thus, for example, certain flavonols have been shown to be required for growth of the pollen tube. If the accumulation of flavonols is suppressed by blocking their biosynthetic pathway, sterile pollens are obtained (Taylor and Jorgensen, 1992).
Both biotic and abiotic signals may result in an accumulation of flavonoids during interaction of a plant with its environment. Thus, for example, UV irradiation leads to an accmnulation of flavonols and flavones. This is achieved by induction of the transcription of the respective flavonoid biosynthesis genes in different species (Kubasek et al., 1992). But also other stress factors such as wounding, extreme temperature variations and water stress may induce flavonoid accumulation and/or gene expression in different species (Hradzina, 1982).
Flavonoids have been assigned a double role in interactions of plants with other organisms. On the one hand, as phenolic compounds flavonoids have a phytoalexin effect against various pathogens and as a deterrent against predators (Harborne and Grayer, 1994), on the other hand they are responsible for the communication between plants of the family of Leguminosae and particular microorganisms. In this respect, flavonoids serve as signaling agents for nitrogen fixing bacteria which then express genes required for establishing a symbiosis with the plant (Redmond et al., 1986). In flowers, leaves, and fruits, the flavonoids and particularly the colored anthocyans but also chalcones, aurones, flavones, and flavonols, are responsible for the coloring and the patterns of various secondary metabolites. Together with other characteristics such as e.g. t:he scent the latter is important for recognition by various animals but also for humans using the plant as decoration or food stuff (Harborne and Grayer, 1994). Furthermore, particular flavonoids such as the flavone apigenin and the flavonol quercetin, have an effect on the auxin transport within a plant (Jacobs and Rubery, 1988) The flavonoid biosynthesis pathway (Fib. 1_A~
The structure of flavonoids includes two aromatic rings (A and B) and a central heterocycle (C) (Fig. 1B). Within the plant, they are synthesized starting from L-phenylalanine via the phenyl propanoid pathway by the enzymatic reaction of phenylalanine ammonia lyase (PAL) and cinnamonic acid 4-h;ydroxylase (4CL). 4-Cumaroyl CoA resulting from this reaction together with 3 molecules of malonyl CoA yields tetrahydroxychalcone. This reaction is catalyzed by chalcone synthase (CHS), the key enzyme of flavonoid biosynthesis (Fig. lA). Generally, tetrahydroxychalcone (THC) is quickly isomerized to yield naringenin (NAR) by the enzyme chalcone isomerase (CHI). Different subsequent reactions generate the anthocyans. Flavones are formed via a side pathway by the action of FNS I or FNS
II, a cytochrome P450 enzyme. This class of enzymes is widespread in nature, and various genes for cytochrome P450 enzymes have been isolated and sequenced from vertebrates, insects, yeasts, fungi, bacteria, and plants.
Flavone synthase uses different flavanones such as NAR or eriodyctol (ERI) as substrates to synthesize the corresponding flavones apigenin (Ap) and luteolin (Lu). For this purpose, a double bond is introduced between positions C2 and C3, as shown in Figure 1B. Flavones may be present in plants in glycosylated as well as in methylated forms.
The formation of flavones from flavanones in vitro has been observed first in enzyme preparations of UV irradiated Petroselium crispum cell suspension cultures. The corresponding enzyme is a soluble 2-oxoglutarate-dependent dioxygenase which has been referred to as flavone synthase I (FNS I). In the flowers of various flavone-producing plants, e.g. Si;nningia cardinalis, Antirrhinum majus, Verbena hybrida, Columnea hybrida, Chrysanthemum morifolium, Gerbera hybrids and osmotically induced cell suspension cultures of Glycine max, this reaction, however, is catalyzed by the above-mentioned FNS
II, an NADPH-dependent microsomal enzyme belonging to the class of P450 cytochromes (Heller and Forkmann, 1994). The formation of flavones in flowers of Gerbera hybrids is regulated by the Fns locus. Flavone synthesis is only detected in lines which carry the dominant allele while no FNS II activity is detectable in homozygous recessive lines (Fig. 2; Martens and Forkmann, 1998).
Three types of pigments are responsible for the color in flowers: betalains, carotenoids, and flavonoids. Betalains are present only in a few families of the Centrospermae in which they are responsible for yellow, orange, red, and purple colors. Carotenoids result in orange and yellow shades and ane the main pigments of most of the orange and yellow flowers. Flavonoids are the most important and most widespread pigments in flowers and plants, respectively. This group includes the coloring anthocyans which are present in the vacuole in glycosylated and often acylated forms. Different anthocyans are able to produce different shades. The color of flowers is further affected by the pH of the vacuole, the complexation with metals and the pattern of glycosylation and acylation, respectively (Forkmann, 1991 ). Another important factor for the generation of the various flower colors is copigmentation of anthocyans with colorless flavonoids, such as flavones or flavonols, or also with tannins (Scott-Moncrieff, 1936).
Anthocyans which are copigmented with flavones may attain different colors depending on the basic structure of the anthocyan which may vary between purple and blue (Asen and Horowitz, 1974; Goto and Kondo, 1991). Moreover, several flavones, such as isoetin, have been identified as yellow flower pigments (Harborne, 1978).
It is an important aim in horticultural plant breeding to develop novel varieties of flowering ornamental plants. In the past, classical methods of breeding have been partly successful in establishing a number of different colors in many economically important ornamental plants. The gene pool of the individual species, however, limits possibilities of such approaches carried out in a natural manner. This is the reason why today there are only a few species showing the whole spectrum of colors. Furthermore, the alteration generated by means of classical methods of breeding cannot be targeted. Since the aesthetic value of a flower is determined by various factors, such as form, scent and color, and an alteration of one of this factors by crossing generally can only be achieved to the expense of similar other, visible characteristics and is extremely lengthy and laborious, an effective way to achieve novel varieties must be utilized. The possibility of altering the color of plant flowers in a targeted manner provides clear advantages as compared to other methods. This is particularly important in an area with a high product turnover in which novelty is an important market factor. For example, the development of blue flowering varieties of the main cut flower species, such as roses, chrysanthemums, carnations, lilies, tulips, and gerbera would lead to a substantial market advantage on the cut flower market, but also on the potted plant market. The possibility of controlling the synthesis of copigments, e.g. flavones, in plants is a beneficial application of the targeted alteration of flower colors. In addition, besides flowers this application may also be applied to fruits and other agricultural plants, e.g. fruit and vegetable plants, and to leaves, e.g. of ornamental plants.
Besides their contribution to the color of flowers, the flavonoids and particularly the flavones also have other biological properties and effects. For example, in some plants they have been found to be a feed stimulant for monophagous and oligophagous insects (Harborne and Grayer, 1994). In most cases, the glycosides exhibit a higher effect than the corresponding aglycones presumably due to an improved solubility of the glycosides. Furthermore, insects are able to distinguish between different sugar residues whereby the active components are further differentiated. In addition, also the basic structure of the aglycones may result in different effects. Compared to many other secondary plant metabolites, the flavonoids and flavones, respectively, obviously have no excessive toxic effect on insects. Nevertheless there are some flavones which already in very low concentrations are able to act as a deterrent for feed insects or to severely inhibit the growth of the animals. In this respect, no effect of the type of glycosylation could be demonstrated. However, an effect of the type of hydroxylation or methoxylation, respectively, of the flavone could be demonstrated (Harborne and Grayer, 1994).
Moreover, several flavones stimulate the egg laying of butterflies on specific plants. It has been shown that egg laying does not occur until the animals have recognized the stimulus. Such stimulating substances include for example flavones the vicenin-2 and various luteolin derivatives. If the synthesis of these substances is blocked in the respective host plants it is possible to inhibit egg laying by the butterflies and, thus, feed damages by their caterpillars.
Utilizing the natural chemical defense mechanisms of the plants may avoid the problems encountered with the use of synthetic insecticides such as e.g.
environmental pollution caused by residues of the substances used in fruits and soil. In addition resistance generation observed with most of the synthetic pesticides is avoided or at least delayed, and the sometimes extensive costs for agents and applications are saved.
Another important biological property of the flavonoids relates to the activation of nodulation genes in various rhizobium species. These bacteria infect leguminous plants and form nitrogen-fixing root nodules. In this process, the flavonoids produced by the host plant act as a "signaling agent" whereby the bacteria induce the process of infection. These plant-specific active compounds also include various flavones such as apigenin, luteolin, and 7,4'-dihydroxyflavone (Firmin et al., 1986; Redmond et al., 1986). Altering the production and delivery of flavones by the root or the flavone pattern, respectively, in this tissue provides a possibility to improve the nitrogen fixation and probably to establish this mechanism also in non-leguminous plants.
Utilizing this natural symbiotic mechanism may reduce nitrogen fertilization and thereby the environmental pollution by washing away of the nutrients.
Moreover, the costs for fertilizers and for their spreading are saved.
Within a plant, several naturally occurring flavonoids such as the flavone apigenin or the flavonols kaempferol and quercitin affect the transport of auxins in different plant tissues and transport systems. In this respect, they act similar to chemical transport inhibitors. As growth regulators of plants the auxins themselves affect cell extension, cell division, apical dominance, reformation of roots and shoot as well as parthenocarpy. An induced, altered flavonoid concentration (endogenous change and/or exogenous application), thus, may have a significant effect on plant growth via their interaction with auxins. This may allow for a substitution of synthetic growth inhibitors.
Moreover, as bioactive substances flavonoids have a non-negligible role in the diet of men and animals. They are found in fruits, vegetables, nuts, seeds, shoots but also in tea and wine. Since some time, anti-allergic, anti-inflammatory, anti-viral, proliferation-reducing and anti-cancer properties are attributed to flavonoids and also to several flavones. But also an effect on the metabolism and the highly complex immune system of humans and animals has been described. In this respect, flavonoids and flavones, respectively, have an effect on a large number of different enzymes (e.g. on hyaluronidase or aldose reductase), they have important enzyme inducing and anti-oxidative properties, and are capable of scavenging free radicals, chelating several metal canons, and have an effect on cellular protein phosphorylation (Middleton and Kandaswami, 1994).
If agricultural plants important for the human and animal nutrition because of their content in health-promoting flavonoids can be improved by a targeted alteration of the content or pattern of the respective compounds this would greatly contribute to a healthy diet of men and animals.
Therefore, it has been an object of the present invention to provide means and methods to alter and control the flavonoid biosynthesis and the formation of flavones, respectively, in plants in a targeted manner in order to e.g. alter the color of a plant flower or to improve the resistance properties and capability to establish symbioses of a plant.
It has been another object of the present invention to provide means and methods useful for a targeted synthesis of defined flavones. Flavones obtained in such manner may find use i.a. in cancer therapy or may contribute to the health of men and animals in the form of medicaments.
According to the present invention, this object has been achieved by the claims.
Therefore, the present invention relates to a nucleic acid sequence encoding a flavone synthase II (FNS II). In one embodiment, the present invention relates to a nucleic acid sequence as shown in SEQ ID NO:1, or to a portion thereof. In another embodiment, the present invention relates to a nucleic acid sequence hybridizing to a nucleic acid sequence as shown in SEQ II) NO:1 or a portion thereof and/or having a homology of at least 40%, more preferably at least 45%, further preferred at least 55% or most preferably at least 65-70% or most preferably a homology of more than 85% on the level of the nucleic acid sequence or amino acid sequence to at least one or more regions (preferably to the whole region) of the sequence as shown in SEQ ID NO:1. Preferably, the nucleic acid sequence encodes a protein or a polypeptide having the biological activity of a flavone synthase. In another embodiment, the present invention relates to a nucleic acid sequence which is degenerated with respect to a nucleic acid sequence according to the above-mentioned embodiments. In a prefen-ed embodiment; the nucleic acid sequence according to the present invention is DNA or RNA and is derived from a flavone-containing plant such as gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S. hybrids). In another preferred embodiment the nucleic acid sequence according to the present invention is a recombinant nucleic acid sequence. Furthermore, the present invention relates to a nucleic acid sequence complementary to the sequence encoding flavone synthase II (FNS In.
Accordingly, the present invention provides an isolated nucleic acid sequence comprising a nucleic acid sequence encoding flavone synthase II (FNS I~ or a functional derivative of said enzyme or a nucleic acid sequence complementary thereto. The term "FNS II enzyme" means enzymes of the flavonoid biosynthetic pathway using flavanones such as naringenin and eriodictyol or also other compounds of this class as a substrate for the synthesis of the corresponding flavones.
Preferred is a nucleic acid according to the present invention which has been isolated from its natural environment or chemically synthesized. Particularly preferred are nucleic acid molecules which are formed or obtained in vitro including genomic DNA fragments, recombinant and synthetic molecules and nucleic acids in combination with heterologous nucleic acids. This also comprises genomic DNA or cDNA or portions thereof encoding FNS II or portions thereof in a reverse orientation to its own or another promoter. Further comprised are naturally occurring, closely related nucleic acid sequences.
The term "nucleic acid sequence encoding a flavone synthase II" is used herein in its most general form and comprises any sequential order of nucleotide bases defining, directly or via a complementary array of bases, an ~unino acid sequence of an FNS II.
A polypeptide having a portion or the complete amino acid sequence of flavone synthase II means a full length FNS II or an active incomplete form thereof.
In another embodiment, the present invention relates to oligonucleotides which may be used as genetic probes or "antisense" molecules for controlling the expression of the corresponding gene in plants or other organisms. An "antisense"
molecule as described herein also comprises a gene construct consisting of a structural, genomic or cDNA gene or a portion thereof in reverse orientation with respect to its own or any other promoter.
In another embodiment, the nucleic acid sequence encoding FNS II or various functional derivatives thereof is used to reduce the activity of endogenous FNS II, or alternatively a nucleic acid sequence encoding said enzyme or various derivatives or portions thereof is used in antisense orientation to reduce the activity of FNS II. Moreover, it is also possible that an antisense transcript of FNS
II or a fragment or a portion of FNS II (e.g. an oligonucleotide molecule) forms a duplex with the whole or portions of the naturally occurring mRNA which specifies the enzyme and thus inhibits an accumulation of or the translation of the mRNA into the active enzyme. Another possibility is the use of ribozymes to inactivate specific nucleic acid sequences.
Alterations of the FNS II activity mentioned herein relate to an increase or decrease of the activity of up to 30% or more preferably 30 to 50% or still more preferably 50 to 75% and most preferably of 75% or even higher or lower, respectively, as compared to the normal, endogenous or existing activity value.
The amount of the activity can be tested easily using the method described in Martens and Forkmann (1998) (see Example 3).
The nucleic acid described in the present invention may also be a ribonucleic acid or a deoxyribonucleic acid existing in the form of a single stranded or double stranded and linear or covalently closed, circular molecule. Generally, the nucleic acid molecule is present in the form of cDNA. The present invention also comprises other nucleic acid molecules hybridizing to the nucleic acid molecules of the invention or specifically to the sequence shown in SEQ m NO:1 or a portion or region thereof under conditions of low~, preferably medium and most preferably high stringency. A particularly preferred embodiment relates to a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ >D
NO:1 or a molecule having a similarity of at least 40%, more preferably at least 45%, still more preferably at least SS% or most preferably at least 65-70% or most preferably a similarity of more than 85% on the level of the mucleic acid sequence or amino acid sequence to at least one or more regions (preferably over the whole region) of the sequence shown in SEQ >Z7 NO:1 and wherein the nucleic acid encodes or is complementary to a sequence encoding an enzyme having FNS II
activity.
Furthermore, the present invention comprises nucleic acid molecules in the form of oligonucleotide primers or competent probes for hybridization with a portion of the nucleic acid molecules described above and specifically to that shown in SEQ
ID NO:1. The hybridization may be earned out under conditions of low, preferably medium and most preferably high stringency. Preferably, said portion corresponds to the 5' or the 3' end of the gene. For the purposes herein, the 5' end is defined as the region extending mainly between the start codon of the structural gene sequence to the medium region of the gene. The 3' end is considered herein as being the region defining the structural genetic sequence between the medium region of the gene and the stop codon. Therefore, it is obvious that oligonucleotides or probes are able to hybridize to the 5' end or the 3' end or to a region which is common to both the S' or the 3' end. The present invention comprises all such probes. Preferred oligonucleotides are presented in Example 4.
The nucleic acid or the complementary form thereof may encode the full length enzyme or a portion or derivative thereof. "Derivative" means single or multiple amino acid substitutions, deletions and/or additions with respect to the naturally occurnng enzyme while, preferably, the flavone synthase II activity is maintained.
In this respect, the nucleic acid according to the present invention comprises the naturally occurnng nucleotide sequence encoding FNS II and single or multiple nucleotide substitutions, deletions, and/or additions. The nucleic acid according to the present invention or the complementary form thereof may also encode a portion of FNS II which is either active or inactive. Such a nucleic acid molecule may be used as an oligonucleotide probe, as a primer for polymerase chain reaction, in different mutagenesis techniques, or for the preparation of antisense molecules.
Furthermore, the present invention relates to a recombinant DNA molecule containing a nucleic acid sequence according to the present invention. In a preferred embodiment, the recombinant DNA molecule is a vector or a vector having a promoter. In a particularly preferred embodiment the promoter is capable of expressing the nucleic acid sequence according to the present invention.
The nucleic acid molecules of the invention may be present in combination with a vector molecule, e.g. an expression vector, in both orientations. In this respect, the term "vector molecule" is used in its most general meaning to comprise any intermediary vehicles of the nucleic acid molecule which enable the transfer of the nucleic acid into cells, particularly in plant cells and/or its integration into a genome. Preferably, these vector molecules or portions thereof are used for integration into a plant genome. Such vector molecules may be replicated and/or expressed in prokaryotic cells and/or in eukaryotic cells. An intermediary vehicle may be for example adapted to the use in electroporation, microprojectile bombardement, in the transfer using agrobacteria or in the insertion via DNA
or RNA viruses. The intermediary vehicle and/or the nucleic acid molecule contained therein may be stably integrated into the plant genome. Additionally, the nucleic acid molecule may contain also a promoter sequence useful for the initiation of expression of the nucleic acid molecule in a cell, particularly in a plant cell. The nucleic acid molecule and the promoter may also be introduced into the cell using different methods (see above).
The present invention also relates to host cells containing the DNA molecules according to the present invention. The host cells may be prokaryotic or eukaryotic cells, particularly yeast cells, insect cells, plant cells, and mammalian cells.
The present invention further relates to a polypeptide encoded by a nucleic acid according to the invention. In a preferred embodiment the present invention relates to a polypeptide having the amino acid sequence as shown in SEQ >D N0:2 or a portion or derivatives thereof. In another preferred embodiment the polypeptide is derived from a flavone-containing plant, such as e.g. from gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S.
hybrids). In a particularly preferred embodiment the polypeptide of the present invention has flavone synthase II activity.
Derivatives in the sense of the present invention are amino acid insertion derivatives, deletion derivatives and/or substitution amino acid variants of the amino acid sequence of SEQ ID N0:2.
Amino acid insertion derivatives of FNS II according to the present invention comprise both amino and carboxyl fusions as well as insertions of single or multiple amino acids within the sequence. Insertion amino acid sequence variants are those in which one or more amino acid residues have been introduced into the protein at a predetermined site, although a random insertion together with appropriate screening of the product is also possible. Deletion variants are characterized by the removal of one or more amino acids from the sequence.
Substitution amino acid variants are those wherein at least one residue of the sequence has been removed and another residue has been introduced at the same site. Typical substitutions are presented in Table 1.

Suitable residues for amino acid substitution Original amino acid Exemplary substitution by Aln Ser Arg Lys Asn Gln; Fps Asp Glu Cys Ser Gln Asn Glu Asp Gly ~'o _ _ .. _ ~s Asn; Gln Ile Leu; Val Leu IIe; Val Lys Arg; G(n; Glu Met Leu; Ile Phe Met; Leu; Tyr S er Thr Thr Ser Trp Tyr .

Tyr Trp; Phe Val IIe; Leu In general, amino acids are substituted by amino acids having similar properties such as hydrophobicity, hydrophilicity, electronegativity, very bulky side chains and the like. Amino acid substitutions generally relate to only a single residue whereas insertions typically are directed to a region of 1 to 10 amino acid residues and deletions to a region of 1 to 20 residues. Preferably, deletions and insertions are carried out on adjacent pairs, e.g. a deletion of two residues or an insertion of two residues.
The amino acid variants described above of derivatives according to the present invention may be prepared easily using known techniques for peptide synthesis such as e.g. by solid phase synthesis and similar methods or by recombinant DNA
manipulations. Techniques for introducing substitution mutations at predetermined sites in DNA having a known or partially known sequence are well-known and include for example M13 mutagenesis. The manipulation of DNA
sequences for the preparation of proteins carrying substitutions, insertions or deletions is detailed for example in Sambrook et al. (1989).
Other examples of recombinant or synthetic mutants and derivatives of FNS II
according to the present invention comprise single or multiple substitutions, deletions and/or additions of any molecule associated with the enzyme such as carbohydrates, lipids and/or proteins or polypeptides.
The terms "analogue" and "derivative" also comprise any functional chemical equivalent of FNS II and also any amino acid derivative as already described above.
Another aspect of the present invention relates to recombinant forms of FNS
II.
Recombinant forms of the enzyme provide the possibility to develop for example more active enzymes or systems for production of various flavones in vitro for the use in various fields such as for example in human medicine. The latter system may be for example of use in cancer research.
In another embodiment, the present invention relates to transgenic plants containing a nucleic acid sequence according to the present invention. In a preferred embodiment, the nucleic acid sequence is suitable for expression and optionally can be controlled or is controlled within the plant in conjunction with its development. In another preferred embodiment the tra.nsgenic plant is selected from the group of flavone-containing plants such as gerbera. (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S. hybrids), contains an endogenous FNS II and further contains a non-endogenous FNS II nucleic acid sequence according to the present invention.
According to the present invention, a nucleic acid sequence encoding an FNS II
or a derivative or portion thereof may be introduced into a plant in one of two possible orientations and may be expressed therein thereby providing the possibility to convert either naringenin (NAR) and/or other suitable substrates, if synthesized within the plant cell, which eventually results in the formation of different flavones. Moreover, the formation of said metabolites may be inhibited by a reduction or elimination of endogenous or existing FNS II activity. In gerbera, the synthesis of flavones results in an alteration of the flower color. Using the flavone-containing, orange colored variety "Th 58" as an example which is heterozygous for the Fns locus (fns+ fns) a color variation from dark red (flavone-free; genotype fns fns) via different shades of orange-red (flavone-containing;
genotype fns+ fns) to a yellow-orange color (very high flavone content;
genotype fns+ fns+) could be demonstrated in autogamy progeny. This experiment may also be applied to other gerbera varieties heterozygous for the Fns locus (see also Example 2). Expression of the nucleic acid sequence in one of two possible orientations within the plant may be constitutively, inducible or dependent on the development and also tissue-specific. The term "expression" is used in its most general meaning to include the production of RNA or both :RNA and protein. It also comprises the partial expression of nucleic acid molecules.
The present invention relates to a method for the preparation of transgenic plants capable of synthesizing FNS II or active mutants or derivatives. Said method comprises the stable transformation of a cell of a suitable plant with a nucleic acid molecule comprising a nucleotide sequence encoding said FNS II under conditions achieving the possible expression of said nucleic acid molecule, regeneration of a transgenic plant from the cell and growth of said transgenic plant for a particular time and under conditions suitable to achieve expression of the nucleic acid.
The transgenic plant may exhibit higher values of FNS II activity compared to the value measured in comparable non-transgenic plants, or the values may be lower compared to those of comparable non-transgenic plants.
One aspect of the present invention relates to a method for the preparation of a transgenic plant having a reduced, endogenous or existing hNS II activity.
This method comprises the stable transformation of a cell of a suitable plant with a nucleic acid molecule comprising a nucleotide sequence encoding a sequence or a complementary sequence of FNS II, the regeneration of a transgenic plant from the cell, and, if necessary, the raising of this transgenic plant under conditions suitable to achieve expression of nucleic acids.
Another aspect of the present invention relates to a method fox the preparation of a genetically engineered plant having a reduced, endogenous or existing FNS II
activity. This method comprises the alteration of the FNS II gene by a modification of the endogenous sequence via homologous recombination starting from an appropriately modified gene of an FNS If or a derivative or portion thereof. The gene is introduced into the plant and a genetically engineered plant is regenerated from the cell.
Another aspect of the present invention relates to a method for the preparation of a transgenic flowering plant having altered flower characteristics. This method comprises the introduction of the nucleic acid sequence according to the present invention into a cell of a suitable flavone-free plant, the regeneration of a transgenic plant from the cell, and raising a transgenic plant for a time and under conditions to achieve the expression of the introduced nucleic acid sequence according to the present invention. The transgenic plant may be for example selected from the group of flavone-containing plants consisting of euphorbia (E.
pulcherrima), cyclamen (Cyclamen persicum), rose (Rosa hybrida), pelargonium (P. spec.), begonia (B. spec.), carnation (Dianthus caryophyllus), and tulip (Tulipa hybrids). In another preferred embodiment, the transgenic plant is capable of expressing an endogenous flavone synthase II. Such a transgenic plant may be for example selected of the group of plants consisting of gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S. hybrids). In another preferred embodiment this endogenous flavone synthase II is coexpressed during expression of the nucleic acid introduced according to the present invention.
In one embodiment, the endogenously existing flavone synthase II activity is reduced by the introduction of the nucleic acid sequence. This method comprises the stable transformation of a cell of a suitable plant with a nucleic acid sequence according to the invention or a sequence complementary thereto, the regeneration of a transgenic plant from the cell and raising this transgenic plant for a time and under conditions suitable to alter the amount of activity of the endogenous or existing FNS II. Preferably, the altered level is lower than the endogenous or existing level of FNS II activity in a comparable non-transgenic plant.
Optionally, for the reduction of the endogenous FNS II activity it is necessary to express the nucleic acid sequence introduced or a complementary sequence thereof. Thus, an expression of the genetic sequence introduced or of its complementary analogue may be required to achieve the desired effect. This substantially means a flowering plant with altered flower characteristics.
In this respect the present invention relates to a method for the preparation of a flowering plant showing different flower characteristics. This method comprises alterations of the FNS II gene by modification of the endogenous sequences via homologous recombination of an appropriately altered gene of FNS II or a derivative or portion thereof, the introduction into the plant cell and the regeneration of the genetically engineered plant from the cell.
Moreover, the nucleic acid molecule according to the present invention may be regulated in a development-depending manner. Generally, an altered inflorescence rules out the possibility of producing a flower having a weaker color or other shades depending on the physiological conditions of the recipient plant.
"Recipient plant" refers to a plant which produces a measurable amount of substrate of FNS II
enzyme or FNS II itself and has the corresponding physiological properties and the genotype necessary for the development of the desired colors. This includes but is not restricted to the following plants: gloxinia (Sinningia Izybrids), snapdragon (Antirrhinium majus), columnea (Columnea hybrids), dahlia (Dahlia variabilis), gloxinia (Sinningia cardinalis), Streptocarpus (Streptocarpus hybridus), verbena (Verbena hybrida), chrysanthemum (Chrysanthemum indicum); peace lily (Spathiphyllum wallisii), petunia (Petunia hybrida), cyclamen (Cyclamen persicum), rose (Rosa hybrids), and pelargonium (P. spec.).
Accordingly, the present invention relates to a method for the preparation of a transgenic plant expressing, to a measurable extent, a recombinant gene encoding FNS II or a portion thereof or carrying a nucleic acid sequence which is substantially complementary to the full length or a portion of the mRNA
molecule which may be easily transcribed, if necessary, to achieve the regulation of FNS II.
This method comprises the stable transformation of a cell of a suitable plant with the isolated nucleic acid comprising a nucleotide sequence encoding FNS II or a derivative or a portion thereof or a sequence complementary to the coding nucleotide sequence, if necessary under conditions allowing an expression of said isolated nucleic acid, and the regeneration of a transgenic plant from the cell.
The skilled artisan immediately appreciates the possibilities for use of the present invention such as e.g. for an increase or decrease in the expression of enzymes which occur naturally in a target plant. This will result in different novel flower color shades, for example various orange and dark red shades.
Therefore, the present invention relates to any transgenic plant containing the full length or a portion of the nucleic acid sequence according to the present invention and/or containing a homologous or related form thereof or an antisense form of any of those described, and in particular those transgenic plants exhibiting varying flower characteristics. The transgenic plants may contain nucleic acid molecules introduced therein comprising a nucleotide sequence encoding FNS II or a complementary sequence thereof. Generally, the nucleic acid is stably introduced into the plant genome although the present invention also comprises the introduction of an FNS II nucleic acid sequence within an autonomously replicating nucleic acid sequence such as for example DNA or RNA viruses capable of replicating in a plant cell. Moreover, the present invention also comprises seeds of the transgenic plant, particularly those containing flavones.
Using the FNS II gene according to the present invention, the biosynthesis of flavonoids and the formation of flavones, respectively, in plants may be altered in a targeted manner in different ways.
To begin with, two different approaches must be considered in the field of plants.
On the one hand, plants are available which naturally form flavones and the glycosides thereof, such as Antirrhinium and Verbena in flowers, Clerodendron and Citrus in leaves, Althaea and Sophora (leguminosae) in roots, and Prunus and Pinus spec. in hardwood (Wollenweber, 1994; Williams and Harborne, 1994).
Besides this very large group there are also some plants which lack flavone synthesis in certain tissues. This is the case e.g. in several flowers of important ornamental plants such as Pelargonium, Cyclamen, and Petunia as well as in apple leaves.
Accordingly, the present invention relates to an altered FNS II activity in plants and other organisms which may be achieved both by increasing and by decreasing the naturally occurnng FNS II activity by an introduction of the sequence of the present invention. A reduction of the amount of FNS II activity may also be referred to as down regulation.
In flavone-containing plants, the flavone synthesis may be up or down regulated or switched off completely in a targeted manner by means of suitable methods.
This has several consequences for the plant. Basically, an alteration of the biosynthetic pathway of this type has an effect on the whole flavone biosynthesis since there is a permanent competition of several enzymes (FNS Ii, FHT, F3'H, F3',5'H) for the substrate (flavonones, e.g. naringenin). This means in detail that e.g. an up-regulation of FNS II reduces the synthesis of flavonoids in a downstream biosynthetic pathway (Fig. lA) whereby for example a paler flower color may be achieved. In addition, by this targeted increase in flavone content which may be restricted to specific tissues, the resistance properties and the capability to form symbioses of the plant may be markedly improved. In contrast, a down-regulation results in an increase in the synthesis of other flavonoids which may be more beneficial for the plant. This may affect both the flavonols important for W
protection and the coloring anthocyans or the resistance-inducing proanthocyanidines and phytoalexins. A complete suppression of flavone formation results in an enhancement of the effects of a down-regulation and may remove possible stimulants for insects and thus contribute to the resistance generation.
An entirely new synthesis of flavones may be achieved by the targeted introduction of FNS II into plants lacking a natural activity. Depending on the substrates present, the flavone content and the flavone pattern may thus be controlled. By establishing this step, flower colors, resistance properties, and the capability to form symbioses with nitrogen-fixing bacteria may be altered in a targeted manner. Moreover, opening a novel biosynthetic pathway may reduce the formation of flavonoids which are less beneficial for the plant (e.g. feed stimulants), and the synthesis of biflavones generated from flavones may be established.
Using these approaches, the flavonoid pattern and content of important flavone-containing or t7avone-free agricultural plants may be altered to optimize their positive properties with respect to the biology of men and animals.
In addition, the present invention relates to methods for the targeted alteration of the flavone content and flavone pattern, respectively, in various plant tissues (flowers, roots, leaves etc.) and other organisms, and thus in general it relates to an alteration of the flavonoid composition, particularly the alteration of flower colors by means of copigmentation, of resistance properties, and of the capability of nodulation in the case of leguminous plants.
In another embodiment, the present invention relates to the use of a polypeptide according to the present invention for the synthesis of flavones. In suitable expression systems, the enzyme itself and thereby eventually the natural flavones may be synthesized starting from appropriate substrates. A possibility is the use of suitable expression systems for obtaining health-promoting, natural flavones.
These expression systems may be of plant origin or consist of cell cultures or yeast cultures, respectively. The expression of FNS II in plants or in cell cultures may be used to directly obtain the respective flavones wherein the yeast expression system may be preferred for obtaining the intact enzyme. Using this enzyme, chemical or natural precursors (flavanones) may then be reacted to form the corresponding flavone. The flavones synthesized in this manner may for example find use in cancer therapy or contribute to human and animal health in the form of medicaments.
The present invention is explained in detail with respect to the following Figures and Examples. The present invention is illustrated with respect to a nucleic acid sequence derived form Gerbera hybrids. It will now be obvious that similar sequences may be isolated easily from various other sources such as e.g. other plants or specific microorganisms. Examples of other flavone-producing plants include but are not restricted to gloxinia (Sinningia hybrids), snapdragon (Antirrhinium majus), columnea (Columnea hybrids), dahlia (Dahlia variabilis), gloxinia (Sinningia cardinalis), Streptocarpus (Streptocarpu.r hybridus), verbena (Verbena hybrida), chrysanthemum (Chrysanthemum indicum), peace lily (Spathiphyllum wallisii). All these nucleic acid sequences encoding, directly or indirectly, an enzyme of the flavonoid biosynthesis pathway and particularly FNS
II are encompassed by the present invention disregarding the source thereof.
FIGURE lA-C shows a schematic representation of the general flavonoid biosynthesis pathway and the chemical structures of several flavonoids.
The enzymes involved are abbreviated in Figs. lA and 1B as follows: CHS =
chalcone synthase; CHI = chalcone isomerase; FHT = flavanone 3-hydroxylase;
DFR = dihydroflavonol 4-reductase; ANS = anthocyanidine synthase; FGT =
flavonoid 3-glycosyl transferase; FNS II = flavone synthase II; FLS = flavonol synthase; F3'H = flavonoid 3'-hydroxylase; F3',5'-H = flavonoid 3',5'-hydroxylase.
The level of flavone formation is particularly indicated (++-+-+) in Figure lA. In the upper portion of Figure 1B the FNS II reaction is shown in the presence of NADPH and several common flavanones. In the lower portion, other important flavonoids are shown. Figure 1C describes the flavonoid biosynthesis pathway as present in Gerbera hybrids. The following abbreviations have been used for the different flavonoids: THC = tetrahydroxychalcone; PHC = pentahydroxychalcone;
NAR = naringenin; ERI = eriodictyol; Ap = apigenin; Lu = luteolin; DHK =
dihydrokaempferol; DHQ = dihydroquercetin; Km = kaempferol; Qu = quercetin;
LPg = leucopelargonidin; LCy = leucocyanidin; Pg = pelargonidin; Cy =
cyanidin.
FIGURE 2 shows the activity or the lack of activity, respectively, of FNS II
in enzyme extract from petals of different gerbera lines: "Th 58" (genotype fns+
fns), "147-150" (fns+ .), and "147-146" (genotype fns fns). The lines "147-150" and "147-146" are autogamy progeny of "Th 58". The FNS II activity was measured by means of the turnover of '4C-labeled naringenin to the corresponding flavone apigemn.
FIGURE 3 shows the FNS II activity (~) and the accumulation of flavones (p) in line "Th 58" (fns+ fns) over different developmental stages of the flower. The different flower stages are defined in Example 2. The flavone content was determined by extraction with ethylacetate and HPLC detecaion as described in Martens and Forkmann (1998).
FIGURE 4A+B (according to Schopfer and Ebel, 1998) shows the known structure of cytochrome P450 sequences containing regions of high sequence conservation. The prolin-rich, the oxygen binding and the heme binding regions are indicated. In Fig. 4B the heme binding region is shown in detail in addition to the primers derived therefrom for DD-RT PCR. A set of eight non-degenerated 5' primers was prepared according to the putative nucleotide sequence.
FIGURE 5 shows a schematic representation of the different cytochrome P450 DNA fragments generated. All clones contain the heme binding site indicated.
pDDd7a: a 358 by fragment could be generated via PCR using the oligonucleotides "Decamer d7" and "Oligo A" with a DNA template recovered from a differentially expressed band.
pTABATA: a 1519 by fragment was isolated starting from gerbera "Th 58" cDNA
via a PCR-supported RACE method using oligonucleotides "GSP7", "GSP8", GSP9", and "AAP" (GIBCO-BRL) or by "backrace", respectively.
pCYPFNS 1: a 1589 by fragment containing an open reading frame was isolated via PCR using oligonucleotides "CypFNS 1 H" and "CypFNS 1 R". cDNA of gerbera "Th 58" was used as the template.
FIGURES 6 and 7 are representations of the nucleic acid and the amino acid sequence derived therefrom, respectively, of the full length clone. The start codon and the different stop codons are indicated separately.
Figure 8 shows a diagram of the restriction sites present for standard restriction enzymes.
FIGURE 9 shows a FNS II assay using yeast microsomes. [14C]-naringenin was used as the substrate. Microsomes were prepared from transformed yeasts (INV Sc 1 - CypFNS 1 ) and untransformed yeasts (INV Sc 1 ). The autoradiograph shows the conversion of [14C]-naringenin to the corresponding flavone, [14C]-apigenin, using an extract of transformed yeast (INVScl -- CypFNSI). In the control experiment (INVScl) no activity was measured. The product was identified by co-chromatography with authentic apigenin in four different eluents.
FIGURE 10 shows an autoradiography of an RNA gel blot hybridized with a 32P-labeled cDNA of insert CypFNS 1. Each lane contains 20 ~g of total RNA which was applied as follows: (1) Simm (genotype fns+ .), (2) Delphi (fns+ .), (3) T3 (fns fns), (4) 147-150 (fns+ .), (5) clivia (fns fns), (6) 147-146 (fns fns), (7) Regina (fns+ .), (8) gerbera leaves (fns fns), (9) pool of 10 (fns+ .), (10) pool of 10 (fns fns).

l~~Tora,-;.~ta Chemicals, enzymes and radiochemicals Naringenin, eriodictyol, apigenin, and luteolin were obtained from Carl Roth (Karlsruhe, Germany). [14C]-naringenin was prepared from ['4C]-malonyl CoA
(ARC, St. Louis, USA) and p-cumaroyl CoA (Dr. Werner Heller, GSF, Neuherberg, Germany) according to the method described in Britsch et al.
(1981) using partially purified chalcone synthase (CHS) and chalcone isomerase from parsley suspension culture. All other enzymes were obtained from commercial suppliers and used according to their specifications.
Bacterial and yeast strains The following Escherichia coli strains were used: TOP10F' and TOP10, both from Invitrogen (Groningen, Netherlands). In addition, the following yeast strain was used: INVScl (Invitrogen).
Cloning vectors pCR2.1 and pYES2 were obtained from lnvitrogen.
The ligation of insert and vector pCR2.1 and the transformation of bacteria, respectively, was carried out according to the instructions of the manufacturer.
Plant materials Chemogenetically defined Gerbera clonal varieties (Tyrach and Horn, 1997) and autogamy progeny of line "Th 58" were available. In addition, the current cut gerbera varieties "Regina" of Terra Nigra company (DeKwakel, Netherlands) and "Delphi" of Florist company (DeKwakel, Netherlands) were included. A detailed description of the plant material may be found in Table 2.

Plant material used Gerbera line Genotype Source ~5g fns ns Tyrach and Horn, 1997 Delphi fns+ fns Florist, Tyrach and Horn, Sign fnsi fns Tyrach and Horn, 1997 T3 fns &~s T;yrach and Horn, 1997 147-150 fns+ fns Th 58 x S

Clivia fns fns T;yrach and Horn, 1997 147-146 fns fits Th 58 x S

Regina fnsi . Terra Nigra Regina leaves fns fns Terra Nigra pool of 10 (147-...)fns' . Th 58 x S

pool of 10 (147_,._?fns fns Th 58 x S

Plant cultivation, crossing methods and flower stages Plants of Gerbera hybrids were cultivated in a green house under conditions common in practice. The day length was at least 14 h at a light intensity of 10,000 lux and at 22°C.
Autogamy of the variety "Th 58" (genotype fns+ fns) was carried out within the same inflorescence or between inflorescences of the same plant. This autogamy experiment may be carried out with any variety or line heterozygous for the Fns locus. The corresponding chemogenetic and biochemical methods are detailed in Tyrach and Horn (1997) and Martens and Forkmann (1998). Controlled flowering was achieved by glassine bags put over the flowers. Ideally, the pollinations were repeated up to four times in daily intervals. Further descriptions with respect to the methods of pollination and floral morphology in Gerbera may be found in Maurer ( 1967).
Gerbera flowers were harvested in different developmental stages defined as follows (according to Martens and Forkmann, 1998):
Stage 1: bud closed, petals smaller than 5 mm;
Stage 2: ray flowers visible, 5-10 mm long;
Stage 3: ray flowers 10-15 mm long;
Stage 4: beginning pigmentation, length 15-23 mm;
Stage 5: ligula of ray flowers pigmented, 23-26 mm long;
Stage 6: ray flowers 26-3 S mm long;
Stage 7: inflorescence half open; 35-40 mm long;
Stage 8: inflorescence completely opened, 40-50 mm long;
Stage 9: ray flowers 50-SS mm long;
Stage 10: ray flowers 55-60 mm long;
Stage 11: senescent inflorescence, SS-60 mm long.
FX A MP1.F ~
Biochemical and enzymolo~ical characterization of the autogamy progeny Known standard methods (Marbry et al., 1970; Harborne, 19fi7) were used for the extraction and identification of flavonoids. Flavones were additionally detected under LTV light (243 nm) prior and after vaporization with ammonia. Flavanones were identified by reduction with sodium borohydride and subsequent treatment with hydrochloric acid vapors (Eigen et al., 1957).
Thin layer chromatography was carried out on precoated cellulose plates 61440 of Schleicher & Schull company (Dassel, Germany). For this purpose, the following eluents were used: (1) chloroform-acetic acid-water (10:9:1); (2) 30% acetic acid;
(3) acetic acid-hydrochloric acid-water (30:3:10); and (4) tert-butanol-acetic acid-water (3:1:1).
The flavone content of buds and flowers during development was determined by extraction of the pigments from petals of the different stages using ethylacetate.
The ratio of tissue to extracting agent was 1:40 (g/ml) and the; period of extraction was 48 h at 4°C in the dark. Characterization and quantification were performed using HPLC. 10 ~1 of 75% methanolic extract were applied to and separated on a Spherisorb ODS II column (particle size 5 Vim, 250 x 4.6 mm, Bischoff, Leonberg, Germany) (Lange et al., 1994). The detection was done using a diode array detector Model 168 (Beckman, Munich, Germany).
Enzyme preparations and FNS II assays were performed as described in Martens and Forkmann (1998). The preparation was carried out in 6.0 ml Tris-HCl buffer (pH 7.5) containing 28 mmoles/1 2-mercaptoethanol and l0 mmoles/1 sodium ascorbate at 4°C with 1.0 g of petals, 0.5 g Dowex (equilibrated in Tris buffer, pH
7.5), and 0.5 g sea sand. After homogenizing in a cooled mortar the homogenate was transferred into Eppendorf tubes and centrifuged twice for 5 min at 10,000 x g. The cleared supernatant was used as raw extract or was used for the precipitation of microsomes with MgCl2 according to Diesperger et al., (1974).
The protein content of the preparations was determined according to the method of Bradford (1976).
The standard assay for FNS II contained in a total volume of 200 pl: 175 pl Tris-HCl buffer (pH 7.5), 0.3 nmol radiolabeled substrate (83 Bq; naringenin), 2.0 nmol of unlabeled substrate, 10 ul of 20 mmoles/1 NADPH and 15 ~1 raw extract or microsomal preparation. After an incubation of 20 min at 25°C the reaction was stopped by addition of 20 pl methanol containing a mixture of the corresponding flavonoids. The extraction of the reaction mixture was carried out twice with and 50 ~l of ethylacetate. The upper phase was chromatographed on cellulose thin layer plates in eluent 1 (see above). The radioactivity was localized and quantified using a Fuji BAS 1000 Bio-Imaging Analyzer (Fuji Photo Filrn Co., Tokio, Japan) and the TINA software package (Raytest, Straubenhardt, Gerniany).
Fig. 2 exemplarily shows the result of the enzyme assays carried out with the Gerbera . variety "Th 58" and the lines "147-150" and "147-146". The corresponding genotypes are shown in Table 2.
Oli~onucleotide synthesis The oligonucleotides were synthesized by Metabion company (Martinsried, Germany). The following oligonucleotides were used (5'-3'):
Oligo A 5'- T(A,C,G)A-3' (SEQ ID NO:3) :

Oligo C 5'- T(A,C,G)G3' : (SEQ lD N0:4) Oligo G 5'-TTfITTTTTT T(A,C,G)G-3' {SEQ ID N0:5) :

Decamer 5'-CGCCATTTGG-3' (SEQ ID N0:6) 1 :

Decamer 5'-CGCCATTCGG-3' 2 : {SEQ lD N0:7) Decamer 5'-CGCCCTTTGG-3' (SEQ ID N0:8) 3 :

Decamer 5'-CGCCCTTCGG-3' (SEG1 ID N0:9) 4 :

Decamer 5'-CGCCGTTTGG-3' (SEQ lD N0:10) 5 :

Decainer6 5'-CGCCGTTCGG-3' (SEQ ID N0:11) :

Decamet 5'-CGCCTTTTGG-3' 7 : (SEQ ID N0:12) Decamer 5'-CGCCTTTCGG-3' (SEQ ID N0:13) 8 :

GSP7 : 5'-ATCTTCAAAGTGTTTCCTCGTTCC-3' (SEQ ID NO:i4) GSPB : 5'-AATGGAACACACACAAAATCTACG3' {SEQ ID N0:15) GSP9 : 5'-TCACCACTGAGAGTTCTCTCATGG-3' (SEQ ID N0:16) AAP : 5'-GGCCACGCGTCGACTAGTACGGGIlGGGIIGGGI1G-3' (SEQ ID No:l7) Backrace 5'-GCCACGCGTCGACTAGTACG-3' (SEQ ID N0:18) :

CypFNSIH 5'-CAAAGGATCCCAACACCATGAATACACTGG3' (SEQ lD N0:19) :

CypFNS1 5'-AGATAGACCGACTGCCATCAAGAAAGG3' (SEQ ID N0:20) R :

The three oligomers and eight decamers were synthesized according to Schopfer and Ebel (1998).

Cloning of a P450 fragment from Gerbera hybrids Isolation of total RNA form Gerbera petals Total RNA from Gerbera petals was isolated according to a method described in Guiliano et al. (1993) from various defined genotypes (fns+ . or fns frcs;
Tab. 2) of stages 2-4 in which the FNS II activity increases (Fig. 3). 1.2 g of plant material frozen in liquid nitrogen was ground to a fine powder in a cooled mortar and transferred into a cooled Corex tube. The tissue was homogenized by thorough vortexing in 3 ml of charged extraction buffer consisting of 4 M guanidinium thiocyanate, 0.15 M sodium acetate {pH 5.3), 0.2% sodium s~ucosinate and 0.7%
13-mercaptoethanol and 2.4 ml water-equilibrated phenol (saturated with 0.1 M
citrate buffer, pH 4.3, Sigma, Deisenhofen, Germany). After addition of 0.6 ml chloroform the thoroughly mixed homogenate was kept on ice for 20 min and then centrifuged at 15,000 x g (Sorvall RC-SB plus; SS34). The removed upper phase was added with 1 vol. of isopropanol and incubated for another 60 min on ice.
After centrifugation for 30 min at 15,000 x g (Sorvall, see above) the upper phase was discarded and the pellet resuspended in sterile HzO. To remove the polysaccharides, the solution was added with 100% ethanol (20% (v/v) final concentration), incubated for 20 min on ice, and centrifuged 10 min at 10,000 x g and 4°C. The supernatant containing the nucleic acids was added with 1/3 vol. of 8 M lithium chloride. After incubation for 30 min on ice centrifugation for 20 min at 15,000 x g was earned out and the supernatant discarded. The precipitated RNA
was washed twice each with 1 ml 80% ethanol and then resuspended in 50 p.l H20 and stored at -70°C. Determination of the RNA concentration was carried out spectrophotometrically at a wave length of 260 nm (Pharmacia Biochrome 4060).
If necessary, poly (A)+ RNA was additionally isolated from the total RNA by two cycles of oligo (dT) cellulose chromatography (Sambrook et a:L., 1989).
Reverse transcription of RNA
5 ~g of total RNA or 500 ng of poly (A)+ RNA isolated from the different genotypes or flower stages, respectively, as described above were transcribed into cDNA in a 25 pl sample using one of the three oligo (dT) primers each by reverse transcriptase (SuperScriptTM II, GIBCO BRL, Paisley, Great Britain). The RNA
was added with 1 ~l of the respective oligo (dT) primer (1 pM final) and water up to a volume of 17 pl. The sample was then denatured at 70°C for 10 min and afterwards placed on ice. After addition of 4 pl 5 x Superscript first strand buffer, 2 ~1 100 mM dithiothreitol, 1 pl 10 mM dNTP mix, the sample was preincubated for 2 min at 42°C. Afterwards, 1 ~l (200 U) of SuperScriptTM reverse transcriptase was pipetted directly into the sample. The reaction was incubated for 60 min at 42°C and then for 15 min at 70°C. This provided the following cDNAs: fns+ A, C
or G and corespondingly for the recessive line fns- A, C or G. These cDNAs were used directly as templates for the PCR sample.
PCR amplification using p450-specific primers The amplification of different cDNAs was performed by means of PCR wherein besides the oligo (dT) anchor primer a second non-degenerated P450-specific primer (Decamer 1-8) was used. The PCR sample contained the following components in a total volume of 20 pl: 6.2 ~ l water, 1 pl 20 x polymerase buffer, 2.5 mM MgCl2, 0.2 pM dNTP mix, 1 pl 35S-ATP [1000 Ci/mmol] (ICN
Pharmaceuticals, Irvine, USA), 0.5 ~M of one of eight decarner primers, 1 pM
of oligo (dT) primer specific for the cDNA, 4 ~l of the cDNA sample described above, and 0.2 ~l 5 U/~1 Replitherm polymerase (Epicentre, Madison, USA). The following PCR parameters were used: denaturation step at 94°C for 10 min, then 40 cycles at 94°C for 30 seconds, 40°C (annealing) for 2 min, and 72°C
(extension) for 30 sequence, followed by a final extension at 72°C for 7 min. 4 ~l of the PCR product were then added with 2 pl formamide loading buffer (80%
formamide; 10 mM EDTA (pH 8.0), 1 mg/ml xylencyanol FF and 1 mg/ml bromophenol Blue, mixed, denatured at 95°C for 2 min, and then placed directly on ice. The sample prepared in this manner were loaded to a 5% denaturing polyacrylamide gel and separated for 3 hours at a maximum of 40 W.
Subsequently, the gel was transferred to Whatman paper and fixed in a gel dryer.
The radioactivity or differential bands, respectively, were localized using a Fuji BAS 1000 Bio-Imaging Analyzer (Fuji) and the TINA software package (Raytest).
Differentially expressed bands at a size of 300 to 500 by were cut together with the Whatman paper from the fixed gel using a sharp blade, transferred to an Eppendorf tube and rehydrated in 100 pl water for 10 min at room temperature.
Subsequently, the tube was incubated at 100°C for 10 min and centrifuged for 2 min at full speed in a table centrifuge to remove residual gel and paper. The supernatant was transferred into a new Eppendorf tube. After addition of 10 ~l M sodium acetate, 5 ~l 10 mg/ml glycogen as a earner and 400 pl 100% ethanol the DNA was precipitated for 60 min at -70°C. The precipitated DNA was then pelleted by centrifugation at 4°C and 14,000 rpm, washed twice with 85%
ice-cold ethanol, dried in air and resuspended in lOpl water. The reamplification of the cDNA obtained in this manner was carried out in PCR samples of 50 pl containing the following components: 27.8 pl water, 2 pl 20 x polymerase buffer, 4 ~l 25 mM MgCl2, 3.2 ul 500 pM dNTP mix, 4 ~l of S~M of the corresponding decamer primer, 4 ~1 25 ~M of the corresponding oligo (dT;l primer, 4 ~I of the eluted DNA described above and 0.5 ~1 SU/~1 Replitherm pol;ymerase (Epicentre).
The PCR parameters were the same as in the first amplification. The PCR
products were separated using a 1.5% agarose gel and the corresponding amplificates were cloned into vector TOPO pCR2.l and then transformed into TOPO lOF' one-shot competent cells (Invitrogen) according to the instructions of the manufacturer. Plasmid isolation from bacteria identified by means of blue-white screening was performed using the Plasmid Miniprep Quantum Prep kit (Bio-Rad, Munich, Germany) according to the instructions of the manufacturer.
The inserts identified after digestion with the appropriate restriction enzymes (e.g.
Eco RI; Boehringer, Mannheim, Germany) and separation on a 1.5% agarose gel having a length between 300 and 500 by were eluted from the gel using the QUIAEX II gel elution kit (QIJIAGEN, Hilden, Germany). These DNA fragments were labeled with 32P using the Rediprime Labelling kit (Amersham, Braunschweig, Germany) and used for Northern blot analyses. DNA sequencing of these and other clone was carried out substantially according to the method described by Sanger et al. (1977) using Sequenase enzyme Version 2.1 (Amersham, Braunschweig, Germany).

Northern blot analysis Total RNA was isolated as described in Example 5. 10 ~g of different total RNA
samples were electrophoresed on a 2.2 M formaldehyde/l.2°,% (w/v) agarose gel.
The running buffer contained 20 mM MOPS (pH 7.0), S mM sodium acetate and 1 mM EDTA (pH 7.0). The RNA was transferred to Hybond-NX membrane (Amersham) according to the instructions of the manufacturer and hybridized with a 32P-labeled Eco RI-Eco RI pDDd7a cDNA fragment. Prehybridization ( 1 to 3 hours at 42°C) and hybridization (16 to 24 hours at 42°C) were performed in SO%
deionized formamide, 5 x SSPE, 5 X Denhardt's, 0.5% SDS. Denatured herring sperm DNA (100 ~g/ml) was added in the hybridization step together with the labeled probe. The filters were washed twice for 15 min at 42°C in 2 x SSPE, 1 SDS (w/v) and then once or twice at 65°C with 1 x SSPE, 1% SDS
(w/v). The radioactivity was localized and quantified using a Fuji BAS 1000 Bio-Imaging Analyzer (Fuji) and the TINA software package (Raytest).
Northern blot analyses revealed that the gene corresponding to cDNA clone pDDd7a is only expressed in lines carrying the fns+ . genotype. In lines having the recessive genotype fns fns no hybridization signal could be detected (Fig.
10).
Moreover, the expression pattern over the different flower stages is parallel to the enzyme activity and the flavone accumulation, respectively, measured in the flowers (Martens and Forkmann, 1998).

Isolation of a full-length clone of pDDd7a cDNA clone pDDd7a is no full length clone but covers only the region from the heme binding site to the poly (A+) end (3' end) of the sequence including several stop codons. To obtain the full length clone of pDDd7a a PC'.R-supported RACE
method according to Frohmann et al. (1988) using the 5' RACE system version 2.0 (GibcoBRL) was used.
First, several gene-specific 5'-RACE primers (GSP7-9) on the basis of pDDd7a and in addition the nested amplification primer "backrace" were constructed.
Using GSP7, the total RNA was transcribed into cDNA according to the method described in Example 5. Subsequently, the first strand product was purified from the excess of nucleotides and GSP7 using the High Pure PCR Product Purification kit (Boehringer Mannheim) according to the instructions of the manufacturer.
To the purified cDNA an oligo-dC tail was added using terminal transferase (TdT).
The tailing sample was as follows: 6.5 ~I water, 5.0 ul 5 x tailing buffer, 2.5 ~l 2 mM dCTP and 10 pl cDNA. This mix was denatured for 3 min at 94°C and then placed on ice for 1 min. The reaction was started by addition of 1 pl TdT and then incubated for 10 min at 37°C. Inactivation of the enzyme was carried out by incubation for 10 min at 65°C. PCR amplification of the dC tailed cDNA
was performed in 0.5 ml thin-walled PCR tubes according to the following protocol:
single denaturation for 2 min at 94°C, 35 subsequent cycles consisting of 1 min at 94°C, 57°C for 1 min, and 72°C for 2 min. A final extension step of 7 min was also performed. The PCR sample contained the following components: 31.5 ~1 water, 5.0 pl 1 CI x PCR buffer, 3.0 ul 25 mM MgCl2, 1.0 ~l 10 mM dNTPs, 2.0 ~.1 10 ~M GSPB, 2.0 pl 10 ~M AAP, 5.0 ~1 dC tailed cDNA and 0.5 ~1 5 U/~l Taq DNA polymerase (Promega, Madison, USA). 15 pl of 5'-RACE product were analyzed on a 1.5% agarose gel using an appropriate lenl,~th marker. Specific single bands in a region of 1.5 kb were cloned and verified by Northern blot and sequence analysis, respectively.
Using the 5'-RACE a specific 1.5 kb fragment (pTABATA) was amplified which hybridizes only with total RNA of gerbera lines having the fns+ . genotype and not with RNA from recessive genotypes. Within the region of the gene-specific primer (GSPB) up to the heme binding site, this novel fragment is homologous to fragment pDDd7a. A full length clone (1698 bp) contains an open reading frame and shows a homology of 58% on the amino acid level to cytochrome P450 clone CYP93B 1 (Akashi et al., 1998).

Expression of pCYPFNS 1 in yeast Construction of pYeCYPFNS 1 A 1.5 kb Bam HI-Eco RI fragment corresponding to pCYPFNS 1 was ligated into Bam HI-Eco RI opened yeast expression vector pYES2. The resulting plasmid referred to as pYeCYPFNS 1 contained the pCYPFNS 1 cDNA fragment in the sense orientation as the insert.
Yeast transformation The yeast strain INVScI was transformed with plasmid pYeCYPFNSl following the protocol according to Gietz et al. (1992). The selection of transformed yeast cells was earned out via a complementation marker.
Preparation of yeast microsomes for flavone synthase II assays Individual colonies of INVScI/pYeCYPFNS1 and INVScl grown on selection medium SGI (20 g glucose (w/v), 1 g peptone (Fluka), 6.7 g yeast nitrogen base without amino acids (Difco) and 20 mg L-tryptophane (Fluka) per liter) were then inoculated in 5 x 5 ml SGI broth and incubated at 200 rpm and 30°C for 24 hours.
At an ODboo of 0.2-0.4 of a 1:10 dilution of the preculture it was completely inoculated into 250 ml YPGE (5 g glucose, 10 g peptone., 10 g yeast extract (Fluka) and 3 vol.% ethanol per liter). The main culture was incubated at 30°C and 120 rpm. At an OD6oo of 0.8 to 1.2 the induction was earned out by addition of ml 200 g/1 sterile galactose solution.
After 12 to 15 hours at an OD6oo of 0.6 to 1.2 of a 1:10 dilution of the main culture the yeast cells were harvested by centrifugation, washed once with TEK (50 mM
Tris-HCI, pH 7.4, 1 mM EDTA, and 0.1 M KCI) and resuspended in TES-B* (50 mM Tris-HCI pH 7.4, 1 mM EDTA, 0.6 mM sorbitol, and 2 mM DTT).
Disruption of the yeast cells was performed at 4°C using 15 g glass beads (Sigma) per sample. The glass beads were then washed three times with 5 ml TES-B* and the combined supernatant was adjusted with 4 M NaCI to a final concentration of 0.15 M. The microsomes were precipitated by addition of 2.5 g PEG-4000 (Fluka) and following a washing step with 2 ml TES-B* were homogenized in 2.5 ml TEG* (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 2 mM DT'T) in a Potter. The resulting homogenate served as microsomal enzyme source for FNS II assays.
The FNS II activity was measured according to the method of Martens and Forkmann (1998). The standard assay for flavone synthase II contained in a total volume of 200 ~l: 140 ~l Tris-HCl buffer (pH 7.5), 0.3 nmoles of radiolabeled substrate (83 Bq; [14C]-naringenin), 10 ~l 20 mmoles/1 NADPH and 50 ~1 of the yeast microsomal preparation. After an incubation for 20 min at 25°C
the reaction was stopped by addition of 20 ul methanol containing a mixture of naringenin and apigenin (product). Extraction of the reaction mixture was carned out twice with 100 or 50 ~1 ethylacetate, respectively. The upper phase was chromatographed on cellulose thin layer plates in eluents 1 to 4 (see above).
The radioactivity was localized and quantified using a Fuji BAS 1000 Bio-Imaging Analyzer (Fuji) and the TINA software package (Raytest).
The enzyme extract prepared from INVScI/pYeCYPFNSl showed a clear FNS II
activity whereas the corresponding fraction from untransformed yeasts showed no activity (Fig. 9). The results of the yeast expression confirm that the cDNA
insert pCYPFNS 1 encodes an FNS II enzyme. Moreover, the result reveals that expression of the enzyme encoded by the Gerbera cDNA clone is sufficient in yeast to achieve a direct formation of flavones. This indicates that only a single enzyme is required for introducing the double bond between C2 and C3 (Fig. 1B) and that the cDNA clone described by Akashi et al., (1998) does not represent FNS II but rather a flavanone 2-hydroxylase.
References AKASHI, T., AOKI, T. and AYABE, S.L, 1998. Identification of a cytochrome P450 cDNA encoding (25)-flavanone 2-hydroxylase of licorice (Glycyrrhiza echinata L; Fabaceae) which represents licodione synthase and flavone synthase II. FEBS Letters 431, 287-290.
ASEN, S. and HOROWITZ, R.M., 1974. Apigenin 4'-O-(3-D-glucoside 7-O-13-D-glucuronide: the copigment in the blue pigment of Centaurea cyanus.
Phytochemistry 13, 1219-1223.
BRADFORD, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding.
Analytical Biochemistry 72, 248-254.
BRITSCH, L., HELLER, W. and GRISEBACH, H., 1981. Conversion of flavanone to flavone, dihydroflavonol and flavonol with an enzyme system from cell cultures of parsley. Zeitschrift fur Naturforschung 36c, 742-750.
DIESPERGER, H., MULLER, C.R. and SANDERMANN, H. jr., 1974. Rapid isolation of a plant microsomal fraction by Mg2+ precipitation. FEBS Letter 43, 15-158.
EIGEN, E., BLITZ, M. and GINSBERG, E., 1957. The detection of some naturally occuring flavanone compounds on paper chromatograms. Archives of Biochemistry and Biophysics 68, 1501.
FIRMIN, J.L., WILSON, K.E., ROSSEN, L. and JOHNSTON, W.B., 1986.
Flavonoid activation of nodulation genes in Rhizobium reversed by other compounds present in plants. Nature 324, 90-92.
FORKMANN, G., 1991. Flavonoids as Flower Pigments: The Formation of the Natural Spectrum and its Extension by Genetic Engineering. .Plant Breeding 106, 1-26.
FROHMAN, M.A., DUSH, M.K. and MARTIN, G.R., 1988. Rapid production of full-length cDNAs from rare transcipts: Amplification using a single gene-specific oligonucleotide primer. Proc. Natl. Acad. Sci. USA 85, 8998-9002.
GIETZ, D., ST. JEAN, A., WOODS, R.A. and ScHIESTL, R,.H., 1992. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res.
20, 1425.
GIULIANO, G., BARTLEY, G.E. and SCOLNIK, P.A., 1993. Regulation of carotenoid biosynthesis during tomato development Plant Cell 5, 379-387.
GOTO, T. and KONDO, T., 1991. Struktur and molekulare Stapelung von Anthocyanen -Variation der Bliitenfarben. Angew. Chem. 103, 17-33.
HARBORNE, J.B., 1967. Comparative Biochemistry of the Flavonoids. Academic Press, New York.
HARBORNE, J.B., 1978. The rare Flavone Isoetin as a Yellow Flower pigment in Heywoodiella ollgocephala and in other Cichorieae. Phytochemistry 17, 915-917.
HARBORNE, J.B. and GRAYER, R.J., 1994. Flavonoids and Insects. In : The Flavonoids - Advances in Research since 1986 (Ed.: J.B. HARBORNE).
Chapman & Hall, London, 589-618.
HELLER, W. and FORKMANN, G., 1994. Biosynthesis of Flavonoids. In : The Flavonoids - Advances in Research since 1986 (Ed.: J.B. HARBORNE).
Chapman & Hall, London, 499-536.
HRAZDINA, G., 1982. Anthocyans. In: The Flavonoids - Advances in Research (Ed.: J.B. HARBORNE and MABRY, T.J.). Chapman & Hall, London, 135-188.
JACOBS, M. and RUBERY, P.H., 1988. Naturally occuring auxin transport regulators. Science 241, 346-349.
KUBASEK, W.L., SHIRLEY, B.W., Mc KILLOP A., GOODMAN, H.M., BRIGGS, W. and AUSUBEL, F.M., 1992. Regulation of flavonoid biosynthethic genes in germinating Arabidopsis seedlings. Plant Cell 4, 1229-1236.
LANGE, B.M., TROST, M., HELLER, W., LANGEBARTELS, C. and SANDERMANN jr, H., 1994. Elicitor-induced formation of free and cell-wall-bound stilbenes in cell-suspension cultures of Scots pine (Pinus sylvestris L.).
Planta 194, 143-148.
MARBRY, T.L., MARKHAM, K.R. and THOMAS, M.B., 1970. The Systematic Identification of Flavonoids. Springer Verlag, Berlin, Heidelberg, New York.
MARTENS, S. and FORKMANN, G., 1998. Genetic Control of Flavone Synthase II Activity in Flowers of Gerbera Hybrids. Phytochemistry 49,1953-1958.
MAURER, J., 1967. Untersuchung zur Bliitenbiologie an Gerbera jamesonii J.
Bolus. Z. Pflanzenziichtg. 59, 288-303.
MIDDLETON JR, E. and KANDASWAMI, C., 1994. The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer. In : The Flavonoids - Advances in Research since 1986 (Ed.: J.B.
HARBORNE). Chapman & Hall, London, 619-652.
REDMOND, J.W., BATLEY, M., DJORDJEVIC, M.A., INNES, R.W., KUEMPEL, P.L and ROLFE, B.G., 1986. Flavones induce expression of nodulation genes in Rhizobium. Nature 323, 632-635.
SAMBROOK, J., FRITSCH, E.F. and MANIAT1S, T., 1989. :Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
SANGER, F., NICKLEN, S. and COULSON, A., 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463-5467.
SCOTT-MONCRIEFF, R., 1936. A biochemical survey of some mendelian factors for flower colour. J. Genet. 32, 117-170.
SCHOPFER, C.R. and EBEL, J., 1998. Identification of elicitor-induced cytocnrome P450s of soybean (Glycine max L.) using differential display of mRNA. Mol. Gen. Genet. 258, 315-322.
TAYLOR, L.P. and JORGENSEN, R., 1992. Conditional male fertility in chalcone synthase deficient petunia. J. Heredity 83, 11-17.
TYRACH, A. and HORN, W., 1997. Inheritance of flower colour and flavonoid pigments in Gerbera. Plant Breeding 116, 377-381.
WILLIAMS, C.A. and HARBORNE, J.B., 1994. Flavone and flavonol glycosides.
In: The Flavonoids - Advances in Research since 1986 (Ed.: J.B. HARBORNE).
Chapman & Hall, London, 337-386.
WOLLENWEBER, E., 1994. Flavone and flavonols. In : The Flavonoids -Advances in Research since 1986 (Ed.: J.B. HARBORNE). Chapman & Hall, London, 259-336.
SEQUENCE LISTING
GENERAL INFORMATION:
APPLICANT:
NAME: Martens, Stefan STREET: Waldweg 14 TOWN: Eching COUNTRY: Germany POSTAL CODE: 83386 APPLICANT:
NAME: Forkmann, Gert STREET: In der Point 17 TOWN: Tiefenbach COUNTRY: Germany POSTAL CODE: 84184 NAME OF THE INVENTION:
Genetic sequence which codes for the flavone synthase II enzyme and use of the same NUMBER OF SEQUENCES: 20 COMPUTER READABLE FORM:
DATA MEDIUM: Diskette COMPUTER: IBM PC-compatible OPERATING SYSTEM: Windows 3.11 SOFTWARE: Microsoft Word 6.0 INFORMATION FOR SEQ ID-NO:1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1697 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID-N0:1:
ATGTCCTAAC ACAACCCAAC ACCATGAATA CACTCCAACT CATCTTCCTC

TCCCAACCTT ACTCTTCCTC TACTGTCTCC CCTACAAAAG AAACCAAAAC

TTCCGCCGTC CCCGCCATCT TTTCCGATCA TCGGCCACCT CCF.CCATCTC

TCCACCAATC CTTCCACGCT CTCTCCACTC GCTACGGCTC TCTAATCCAC

GCTCAGTCCC ATGCGTCGTC GTTTCAACCC CAGACCTCGC CAAAGACTTC

ACGAACTCGC GTTCTCATCA AGAAAACACT CCTTAGCCAT .CGA.CCACATC
TAGCATTTGC ATTCGCACCA TATGGAACTT ACTGGAAGTT CATCAAGAAA

TGGAGCTTTT GGGCACCCAG AATCTCAGCC ATTTCCTACC CATTCGAACC

GCGAGCTTCT TCGAACGTTA ATGGTGAAAT CTAGGGCAAA GGAGAGAGTA

AAGAGTTGTT GAAGTTGACC AACAATGTGA TAAGTCAAAT GATGATGAGC

CGGGGACGAA TAGTGAGGCT GATGAAGCAA AGAATCTTGT TCGGGAAGTG

TTGGACAGTT TAATGTTTCA GATTTCATAT GGTTTTGTAA GAACATAGAT

TTAAGAAGAG GTACGAGGGT ACACATAGAA GATATGATGC TT7.'GCTTGAA

TGGGGAGGGA AGAAAATAGA AGAAGAGGGA AGATAAAAGA TGGTGAAGGG

TTGATATGTT ACTTGATGTT TTGGAGGATG GTAAGGCAGA GATTAAAATT

ACATCAAAGC CTTGATTTTG GACTTTCTTA CAGCTGGGAC GGATACCACC

TTGAATGGGC ACTAGTCGAA TTGATAAACA ACCCGAACGC TC7.'CGAGAAA

AGATTGATCA GGTCATCGGT GATGAGAGGC TAGTTCAAGA ATCAGACACG

CTTATATCCA AGCTATCATA AAGGAAGCCC TACGACTTCA CCC_'ACCAATC

TTCGCAAGTC AACAGAAAAT GTAATTGTTC AGGGGTATGA CATCCCAGCC

TGTTTGTCAA TATTTGGTCC ATTGGAAGAA ACCCTCAATG TTGGGAAACC

TCAAGCCTCA TCGGTTTTTG GATGGTGGTG ACCTTAAAAG CTCTTTAGAT

ACAATTTTCA ACTATTGCCT TTTGGGACGG GGAGGAGAGG GTGTCCTGGT

CCATGAGAGA ACTCTCAGTG GTGATTGCAA ACCTCATACA ATGCTTTGAT

TAGGTGAACG ACTATTGAAT ACAGATGAAC GTGCTGGATT GACGGCTCCA

ATTTTGTGTG TGTTCCATTG GAACGAGGAA ACACTTTGAA GA'.CTCTTGGT
TTTATTTGTT GTTGCTTTCT TGATGGCAGT CGGTCTATCT ATAGGTCATA

ACTCACGTGT TTGAATCTTA ATACGCTTTT AGTACATTGC TTATCGTATA

GCATGAAAAA AAAAAAA
INFORMATION FOR SEQ ID-N0:2:
SEQUENCE CHARACTERISTICS:
LENGTH: 511 amino acids TYPE: amino acid TOPOLOGY: linear MOLECULE TYPE: protein SEQUENCE DESCRIPTION: SEQ ID-N0:2:
Met Asn Thr Leu Gln Leu Ile Phe Leu Leu Ph<= Phe Phe Pro Thr Leu Leu Phe Leu Tyr Cys Leu Pro Tyr Lys Arg Asn Gln Asn His Arg Arg Leu Pro Pro Ser Pro Pro Ser Phe Pro Ile Ile: Gly His Leu His His Leu Gly Pro Leu Ile His Gln Ser Phe His Ala Leu Ser Thr Arg Tyr Gly Ser Leu Ile His Leu Arg Leu Gly Ser Val Pro Cys Val Val Val Ser Thr Pro Asp Leu Ala Lys Asp Phe Leu Lys Thr Asn Glu Leu Ala Phe Ser Ser Arg Lys His Ser Leu Ala Ile Asp His Ile Thr Tyr Gly Val Ala Phe Ala Phe Ala Pro Tyr Gly Thr Tyr Trp Lys Phe Ile Lys Lys Leu Phe Thr Val Glu Leu Leu Gly Thr Gln Asn Leu Ser His Phe Leu Pro Ile Arg Thr His Glu Ile Arg Glu Leu Leu Arg Thr Leu Met Val Lys Ser Arg Ala Lys Glu Arg Val Asn Leu Thr Glu Glu Leu Leu Lys Leu Thr Asn Asn Val Ile Ser Gln Met Met:Met Ser Ile Arg Cys Ser Gly Thr Asn Ser Glu Ala Asp Glu Ala Ly:;Asn Leu Val Arg Glu Val Thr Lys Ile Phe Gly Gln Phe Asn Val Ser Asp Phe Ile Trp Phe Cys Lys Asn Ile Asp Leu Gln Gly Phe Lys Lys Arg Tyr Glu Gly Thr His Arg Arg Tyr Asp Ala Leu Leu Glu Arg Ile Ile Met Gly Arg Glu Glu Asn Arg Arg Arg Gly Lys Ile Lys Asp Gly Glu Gly Lys Asp Phe Leu Asp Met Leu Leu Asp Val Leu Glu Asp Gly Lys Ala Glu Ile Lys Ile Thr Arg Asp His Ile Lys Ala Leu Ile Leu Asp Phe Leu Thr Ala Gly Thr Asp Thr Thr Ala Ile Ala Ile Glu Trp Ala Leu Val Glu Leu Ile Asn Asn Pro Asn Ala Leu Glu Lys Ala Arc3 Gln Glu Ile Asp Gln Val Ile Gly Asp Glu Arg Leu Val Gln Glu Ser Asp Thr Pro Asn Leu Pro Tyr Ile Gln Ala Ile Ile Lys Glu Ala Leu Arg Leu His Pro Pro Ile Pro Met Leu Ile Arg Lys Ser Thr Glu Asn Val Ile Val Gln Gly Tyr Asp IlePro Ala Gly Thr Leu Leu Phe Val Asn Ile Trp Ser Ile Gly Arg AsnPro Gln Cys Trp Glu Thr Pro Leu Glu Phe Lys Pro His Arg Phe LeuAsp Gly Gly Asp Leu Lys Ser Ser Leu Asp Ile Lys Gly His Asn PheGln Leu Leu Pro Phe Gly Thr Gly Arg Arg Gly Cys Pro Gly Val AsnLeu Ala Met Arg Glu Leu Ser Va1 Val Ile Ala Asn Leu Ile Gln CysPhe Asp Trp Asp Val Val Gly Glu Arg Leu Leu Asn Thr Asp Glu Arg Ala Gly Leu Thr Ala Pro Arg Ala Val Asp Phe Val Cys Val Pro Leu Glu Arg Gly Asn Thr Leu Lys Ile Leu Gly Ser Asn INFORMATION FOR SEQ ID-N0:3:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:3:
TTTTTTTTTT NA

INFORMATION FOR SEQ ID-N0:4:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:4:
TTTTTTTTTT NC

INFORMATION FOR SEQ ID-N0:5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:5:
TTTTTTTTTT NG

INFORMATION FOR SEQ ID-N0:6:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:6:
CGCCATTTGG
INFORMATION FOR SEQ ID-N0:7:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:7:
CGCCATTCGG
INFORMATION FOR SEQ ID-NO: B:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:8:
CGCCCTTTGG
INFORMATION FOR SEQ ID-N0:9:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:9:
CGCCCTTCGG
INFORMATION FOR SEQ ID-NO:10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single i'OPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-NO:10:
_._~.- ~-._ ~__~, CGCCGTTTGG

INFORMATION FOR SEQ ID-N0:11:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-NO:11:
CGCCGTTCGG

INFORMATION F'OR SEQ ID-N0:12:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:12:
CGCCTTTTGG

INFORMATION FOR SEQ ID-N0:13:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:13:
CGCCTTTCGG

INFORMATION FOR SEQ ID-N0:14:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:14:
ATCTTCAAAG TGTTTCCTCG TTCC

INFORMATION FOR SEQ ID-N0:15:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:15:
AATGGAACAC ACACAAAATC TACO

INFORMATION FOR SEQ ID-N0:16:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:16:
TCACCACTGA GAGTTCTCTC ATGG

INFORMATION FOR SEQ ID-N0:17:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:17:
GGCCACGCGT CGACTAGTAC GGGNNGGGNN GGGNNG

CHARACTERISTIC:
NAME / KEY: other characteristics LOCATION:24 OTHER INFORMATION: N is i CHARACTERISTIC:
NAME / KEY: other characteristics LOCATION:25 OTHER INFORMATION: N is i CHARACTERISTIC:
NAME / KEY: other characteristics LOCATION:29 OTHER INFORMATION: N is i MERKMAL:
CHARACTERISTIC:
NAME / KEY: other characteristics LOCATION:30 OTHER INFORMATION: N is i CHARACTERISTIC:
NAME / KEY: other characteristics LOCATION:34 OTHER INFORMATION: N is i CHARACTERISTIC:
NAME / KEY: other characteristics LOCATION:35 OTHER INFORMATION: N is i INFORMATION FOR SEQ ID-N0:18:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:18:
GCCACGCGTC GACTAGTACG

INFORMATION FOR SEQ ID-N0:19:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:19:
CAAAGGATCC CAACACCATG AATACACTCC

INFORMATION FOR SEQ ID-N0:20:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear MOLECULE TYPE: synthetic oligonucleotide SEQUENCE DESCRIPTION: SEQ ID-N0:20:
AGATAGACCG ACTGCCATCA AGAAAGC

Claims (25)

1. A nucleic acid sequence encoding a flavone synthase II (FNS II) selected from the group consisting of:
(a) the nucleic acid sequence of SEQ ID NO:1 or a portion thereof encoding a protein or a polypeptide having the biological activity of a flavone synthase II, (b) a nucleic acid sequence hybridizing under highly stringent conditions to the nucleic acid sequence of (a) and/or having a homology of at least 40% to this sequence and encoding a protein or polypeptide having the biological activity of flavone synthase II, (c) a nucleic acid sequence which is degenerated with respect to a nucleic acid sequence according to (a) or (b).
2. A nucleic acid sequence which is complementary to the nucleic acid sequence according to claim 1.
3. A nucleic acid sequence according to claim 1 or claim 2 wherein the nucleic acid sequence is DNA or RNA.
4. A nucleic acid sequence according to claim 1 wherein the nucleic acid sequence is derived from a plant from the group of plants consisting of gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S. hybrids).
5. A recombinant DNA molecule containing a nucleic acid sequence according to any of the claims 1 to 4.
6. A recombinant DNA molecule according to claim 5 wherein the recombinant DNA
molecule is a vector or a vector containing a promoter.
7. A host cells containing a DNA molecule according to claim 6.
8. A host cell according to claim 7 which is a bacterial cell, a yeast cell, an insect cell, a plant cell, or a mammalian cell.
9. A polypeptide encoded by a nucleic acid sequence according to any one of claims 1 to 4.
10. A polypeptide containing a portion or the full length amino acid sequence of SEQ ID
NO:2 or derivatives thereof.
11. A polypeptide according to claim 10 wherein the polypeptide has flavone synthase II
activity.
12. A polypeptide according to claim 11 wherein the polypeptide is derived from a plant of the group of plants consisting of gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S. hybrids).
13. A transgenic plant containing a nucleic acid sequence according to any one of claims 1 to 4.
14. A transgenic plant according to claim 13 wherein the nucleic acid sequence is suitable for expression and wherein said expression optionally may be regulated or is developmentally regulated.
15. A transgenic plant according to any one of claims 13 or 14 selected from the group of plants consisting of gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S.
hybrids).
16. A method for the preparation of a transgenic plant having an altered flower color comprising introducing a nucleic acid sequence according to any one of claims 1 to 4 into a cell of a suitable plant and regenerating a transgenic plant from said cell and raising this transgenic plant over a suitable period of time and under conditions suitable for the expression of the nucleic acid sequence introduced.
17. A method according to claim 16 wherein the nucleic acid sequence introduced is expressed within the plant.
18. A method according to claim 16 or 17 wherein the transgenic plant is selected from the group of plants consisting of euphorbia (E. pulcherrima), cyclamen (Cyclamen persicum), rose (Rosa hybrida), pelargonium (P. spec.), begonia (B. spec.), carnation (Dianthus caryophyllus), and tulip (Tulipa hybrids).
19. A method according to claim 16 or claim 17 wherein the plant is capable of expressing an endogenous flavone synthase II (FNS II] which is coexpressed during expression of the nucleic acid sequence introduced.
20. A method according to claim 19 wherein the transgenic plant is selected from the group of plants consisting of gerbera (Gerbera hybrids), aster (Callistephus chinensis), snapdragon (Antirrhinium majus), chrysanthemum (Chrysanthemum indicum), dahlia (Dahlia hybrids), gloxinia (Sinningia hybrids), verbena (Verbena hybrids), and Streptocarpus (S. hybrids).
21. A method according to claim 19 or claim 20 wherein the endogenous flavone synthase II (FNS II) activity is reduced by the introduction of the nucleic acid sequence.
22. The use of a polypeptide according to any one of claims 9 to 12 for flavone synthesis.
23. The use according to claim 22 wherein the flavones are used as a medicament.
24. The use according to claim 23 wherein the flavones are used in cancer therapy.
25. The use according to claim 22 wherein the flavones are employed as bioactive substances.
CA002370387A 1999-04-22 2000-04-14 Genetic sequence which codes for the flavon synthase ii enzyme and use of the same Abandoned CA2370387A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19918365.1 1999-04-22
DE19918365A DE19918365A1 (en) 1999-04-22 1999-04-22 New nucleic acid encoding flavone synthase II, useful e.g. for producing transgenic plants with altered flower color or flavone content
PCT/DE2000/001214 WO2000065073A2 (en) 1999-04-22 2000-04-14 Genetic sequence which codes for the flavon synthase ii enzyme and use of the same

Publications (1)

Publication Number Publication Date
CA2370387A1 true CA2370387A1 (en) 2000-11-02

Family

ID=7905553

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370387A Abandoned CA2370387A1 (en) 1999-04-22 2000-04-14 Genetic sequence which codes for the flavon synthase ii enzyme and use of the same

Country Status (6)

Country Link
EP (1) EP1190077A2 (en)
JP (1) JP2002542789A (en)
AU (1) AU5207200A (en)
CA (1) CA2370387A1 (en)
DE (1) DE19918365A1 (en)
WO (1) WO2000065073A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119252B2 (en) 1999-01-29 2006-10-10 Suntory Limited DNAs coding for flavone synthesis, methods of using flavone synthase DNAS, and plants, flowers, and vectors containing flavone synthase DNAs

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005201464C1 (en) * 1999-01-29 2008-12-11 Suntory Holdings Limited Gene encoding flavone synthase
WO2002086110A2 (en) * 2001-04-20 2002-10-31 Technische Universität München Flavone synthase i enzymes and the use thereof
WO2006010117A2 (en) * 2004-07-10 2006-01-26 The Research Foundation Of State University Of New York Production of flavonoids by recombinant microorganisms
CN100422336C (en) * 2005-06-28 2008-10-01 北京林业大学 Transgenic method of ground cover chrysanthemum mediated by Agrobacterium tumefaciens
USPP21595P3 (en) * 2008-12-19 2010-12-28 International Flower Developments Pty Ltd. Dianthus plant named ‘Floriagate’
JPWO2013125530A1 (en) * 2012-02-24 2015-07-30 サントリーホールディングス株式会社 Torenia-derived promoter that functions in petals
CN114107071A (en) * 2021-12-14 2022-03-01 山西省农业科学院园艺研究所 A kind of separation and purification method of cyclamen fusarium wilt pathogen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60199817A (en) * 1984-03-23 1985-10-09 Rikagaku Kenkyusho anticancer drug
JPS62215581A (en) * 1986-03-18 1987-09-22 Koichi Shiyudo Flavone carboxylic acid derivative
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
KR100245488B1 (en) * 1992-03-02 2000-02-15 히라타 다다시 Novel plant gene
US5336685A (en) * 1993-04-12 1994-08-09 Sloan-Kettering Institute For Cancer Research Use of flavonoids to treat multidrug resistant cancer cells
JPH0725761A (en) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd Agent for protecting cartilage
JPH08104628A (en) * 1994-10-04 1996-04-23 Sumitomo Pharmaceut Co Ltd Matrix metalloprotease inhibitor
JP3798043B2 (en) * 1995-07-12 2006-07-19 大鵬薬品工業株式会社 2-thioflavone derivative and method for producing the same
JPH09224671A (en) * 1996-02-19 1997-09-02 Mitsui Gyosai Shokubutsu Bio Kenkyusho:Kk Dna coding new cytochrome p450
AUPN838696A0 (en) * 1996-03-01 1996-03-21 Florigene Limited Genetic sequences encoding flavonoid pathway enzymes and uses therefor
JPH09301915A (en) * 1996-05-08 1997-11-25 Sankyo Co Ltd Flavone and naphthalene derivative
JP4368005B2 (en) * 1999-01-29 2009-11-18 インターナショナル フラワー ディベロプメンツ プロプライアタリー リミティド Gene encoding flavone synthase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119252B2 (en) 1999-01-29 2006-10-10 Suntory Limited DNAs coding for flavone synthesis, methods of using flavone synthase DNAS, and plants, flowers, and vectors containing flavone synthase DNAs
US7422881B2 (en) 1999-01-29 2008-09-09 International Flower Developments Proprietary Limited DNAs coding for flavone synthases, methods of using flavone synthase DNAs, and plants, flowers, and vectors containing flavone synthase DNAs
US7465569B2 (en) 1999-01-29 2008-12-16 International Flower Developments Proprietary Limited Flavone synthases, methods of using flavone synthases, and plants expressing flavone synthases
US7507566B2 (en) 1999-01-29 2009-03-24 International Flower Developments Proprietary Limited Flavone synthases, methods of using flavone synthases, and plants expressing flavone synthases

Also Published As

Publication number Publication date
JP2002542789A (en) 2002-12-17
WO2000065073A2 (en) 2000-11-02
DE19918365A1 (en) 2000-10-26
EP1190077A2 (en) 2002-03-27
AU5207200A (en) 2000-11-10
WO2000065073A3 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
US7465569B2 (en) Flavone synthases, methods of using flavone synthases, and plants expressing flavone synthases
KR19980702173A (en) Genes encoding proteins with acyl transfer activity
WO2013108794A1 (en) Novel glycosyltransferase gene and use thereof
JPH07505772A (en) Gene sequences encoding enzymes of the flavonoid pathway and their uses
CA2370387A1 (en) Genetic sequence which codes for the flavon synthase ii enzyme and use of the same
Yu et al. Flavonoid compounds in flowers: genetics and biochemistry
WO2002086110A2 (en) Flavone synthase i enzymes and the use thereof
Davies et al. Generation of new ornamental varieties through genetic modification of pigment biosynthesis
KR20010071128A (en) Gene encoding flavone synthase
JPH05184370A (en) Flavonoid hydroxylase gene
DE10119432A1 (en) New nucleic acid encoding flavone synthase I, useful e.g. for preparing transgenic plants with altered flavone content, also derived enzyme used for flavone production
AU2005201464C1 (en) Gene encoding flavone synthase
Marshall et al. Generation of New Ornamental Varieties Through Genetic Modification of Pigment Biosynthesis
AU2005246960A1 (en) Genes coding for flavone synthases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead